A new group of biotech lung
drugs that have produced promising results in clinical tests are now up against
the issue of how cost-effective that are. The first is
likely to be launched next year by GlaxoSmithKline.
Rival firms including Teva
Pharmaceutical Industries and AstraZeneca are racing to develop
similar injectable drugs for patients with severe asthma, who do not respond
adequately to traditional inhalers. It is all in pursuit of a new market that
analysts believe may be worth around $7.5 billion in annual sales. GSK, the
leader in asthma treatments since launching its Ventolin inhaler in 1969,
consolidated its position in the new field by presenting late-stage Phase III
data on its experimental drug mepolizumab at the European Respiratory Society
congress in Munich on Monday.
As Gsk planned cost-effectiveness studies to show the value of its
new product, documentations and research that goes into the whole process is
very scientific and extensive. This is called the Real World Evidence Solutions (RWE).
The Turacoz Healthcare
Solution’s team comprises of multidisciplinary professionals who are
highly experienced in developing documents in real world evidence settings. Our
RWE experts can provide information at every stage of a drug’s development by
providing a thorough research, understanding of disease, treatment patterns and
performance of the product. RWE solutions are the combination of the best
available research (primary and secondary) evidence with clinical experience
along with ascertaining patient needs.
After testing the efficacy and safety of a drug for clinical trials,
the drug comes to the market. The health care stakeholders have to think beyond
the randomized controlled trials (RCTs) for making the drug worthy for the
payers: private insurance companies, government or individuals. In the broader
sense only efficacy is not sufficient for the drug to perform well and
contribute to the healthcare. Assessing effectiveness is an equally important
to convince the stakeholders and policy makers to include the drug in the
treatment guidelines and adapt for the state prescription. The RWE is the
comprehensive understanding about the working of the drug outside the
controlled clinical trial environment.
No comments:
Post a Comment